Amniotic Membrane Market to Gain from Increase in Number of Eye Surgeries

Pune, India, August 2019, MRFR Press Release/- Market Research Future has Published a Cooked Research Report on the Global Amniotic Membrane Market.

Overview:

Amniotic membrane is quite important for body to initiate healing. It is a combination of tissues and cells, which acts as a foundation for re-growth of soft tissues. Amniotic membrane has wide-scale utility in eye surgery that acts like a biological bandage. The process heals or replaces eye tissues that are damaged. The global amniotic membrane market is all set to garner USD 1,210.9 million during the forecast period (2018-2023) with a CAGR of 12.16%. Market Research Future (MRFR) declared the possibility for the amniotic membrane market exceeding the predicted valuation is quite high.

The amniotic membrane market can rely on substantial surge in amniotic membrane-based transplantations globally. Also, health-related awareness is on the rise, which is expected to spur the global market growth.

Segmentation:

MRFR’s analysis of the amniotic membrane market is based on an extensive segmentation that includes type, application, and end-user. This segmentation gets solid backup from the value-wise and volume-wise analysis of the market.

Based on the type, the global amniotic membrane market can be segmented into cryopreserved and lyophilized. The cryopreservation amniotic membrane segment has better potential to lead the market with an impressive CAGR to reach USD 1,090.08million by the end of 2023. This is expected to get driven by the rising number of ocular surgeries. The lyophilized amniotic membrane segment, on the other hand, can project the highest CAGR of 14.18% during the forecast period. This growth is expected to rely mostly on rising number of surgeries, reconstruction procedures, cosmetic surgeries, and venous & pressure leg ulcers.

Based on the application, the global amniotic membrane market can be segmented into surgical wounds, ophthalmology, stem cell biology, regenerative medicine, and others. The ophthalmology segment is expected to fetch in substantial market due to wide-scale use of amniotic membrane in the segment.

Based on the end-user, the amniotic membrane market can be segmented into hospitals & clinics and others. The hospitals & clinics segment is expected to gain more as patients prefer the segment more. 

Access Report Details @ https://www.marketresearchfuture.com/reports/amniotic-membrane-market-5645

Regional Analysis

MRFR in their region-specific take on the global amniotic membrane market includes namely, the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). This region-specific segmentation allows a closer look at the growth pockets that unravels later market possibilities.

The Americas had the largest market share and it covered around 37.6% in 2017 and at present, it is slated to score an impressive CAGR of 13.28%during the forecast period. The APAC market is geared up to record the fastest CAGR during the forecast period. It has a huge market potential and can achieve 13.60% CAGR during the forecast period.

Europe has the potential to surpass USD 681.71 million valuation by 2023. Several issues like pterygium, cicatricial pemphigoid & Stevens-Johnson syndrome, conjunctival surface reconstruction, persistent epithelial defects with ulceration, and ocular surface reconstruction in patients with chemical & thermal burns in Europe are steering the amniotic membrane market growth in Europe. Germany makes a major impact and France is following Germany’s lead.

Competitive Landscape:

Several companies are experiencing substantial growth due to the surge in the ingress level of the amniotic membrane market. These companies have been profiled by MRFR in their report on the same market for a better understanding of strategic moves and trends that can inspire market change. These companies are Applied Biologics (US), Alliqua BioMedical, Inc. (US), Integra LifeSciences (US), Skye Biologics Inc. (California), MiMedx (US), Amniox Medical, Inc. (Florida), Katena Products, Inc. (US), Human Regenerative Technologies, LLC (US), Amnio Technology, LLC (US), and Osiris Therapeutics, Inc. (US).

• In July 2019, Americord Registry launched a new stem cell banking product Placental Tissue 2.0, which can be used to store live amniotic membrane (AM). The system is first-of-its-kind. The company came to limelight as the first family cord blood banks to assist in storage of placental tissue.